I logged into a Zoom meeting wearing a fuzzy robe. Greetings and welcome to another semi-regular column on the Covid-19 pandemic. In this edition: Will #JPM21 be a thing? Some straight talk from Alexis Borisy, Daphne Zohar, and Abbie Celniker; and another biotech buyside investor survey.

Three months ago, thousands of biopharma people and related hangers-on (including a bunch of STAT journalists) were packing suitcases and preparing to board planes to San Francisco. We were all traveling to the annual J.P. Morgan Healthcare Conference and the orbiting meetings and festivities that make “JPM Week” the industry’s largest convocation.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • I will plan to attend JPM2021. Anything could happen between now and then but it’s too valuable to write off at this time.

  • Perhaps slimming down JPM week would reduce the price gouging from SF hotels and restaurants.

Comments are closed.

Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy